Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.

@article{Chester2014BiomarkerCU,
  title={Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.},
  author={C. Chester and Serena Chang and J. Kurland and Idit Sagiv-Barfi and D. Czerwinski and Amanda Rajapaksa and E. Waller and Mohith Sadaram and Lori Richards and L. Cohen and C. M. Ahlers and M. Jure-Kunkel and H. Maecker and R. Levy and H. Kohrt},
  journal={Journal of Clinical Oncology},
  year={2014},
  volume={32},
  pages={3017-3017}
}
  • C. Chester, Serena Chang, +12 authors H. Kohrt
  • Published 2014
  • Medicine
  • Journal of Clinical Oncology
  • 3017 Background: Anti-CD137 antibody was shown in both murine cancer models and in a first-in-human, phase I trial (Sznol et al., 2008) to increase peripheral activated CD8 T cells and IFN-inducible genes, thereby facilitating a cytolytic, antitumor, Th1 response. A multiparametric immune pharmacodynamic assessment of the effects of anti-CD137 therapy has not been previously performed. Methods: We employed the novel technology of mass cytometry time of flight (CyTOF) to investigate the patient… CONTINUE READING
    9 Citations
    Cancer Immunotherapy Highlights from the 2014 ASCO Meeting
    • 25
    • PDF
    Combination cancer immunotherapy and new immunomodulatory targets
    • 696
    • PDF
    Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
    • 96
    Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
    • 84
    • PDF
    Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.
    • 1
    Melanoma immunotherapy: strategies to overcome pharmacological resistance
    • 3